GENE | polymorphism | N° of acute rejection episodes |
---|---|---|
CYP3A5 | AG (n = 12) (24.4%) | 5* (41.6%) |
GG (n = 37) (75.5%) | 3 (1.0%) | |
CYP3A4B | AA (n = 43) (87.7%) | 7 (16.2%) |
AG (n = 6) (12.2%) | 1 (16.6%) | |
SXR A7635G | AA (n = 16) (32.6%) | 2 (12.5%) |
AG (n = 24) (48.9%) | 6 (25.0%) | |
GG (n = 9) (18.3%) | 0* (0.0%) | |
SXR RS rs3842689 | In/in (n = 19) (38.7%) | 3 (12.9%) |
In/del (n = 22) (44.8%) | 4 (18.1%) | |
Del/del (n = 8) (16.32%) | 1 (12.5%) | |
ABCB1 C1236T | CC (n = 18) (36.7%) | 3 (16.6%) |
CT (n = 19) (38.7%) | 2 (10.5%) | |
TT (n = 12) (24.4%) | 3 (0.25%) | |
ABCB1 G2677T/A | GG (n = 16) (32.6%) | 2 (12.5%) |
GT/A (n = 26) (53.0%) | 5 (19.2%) | |
TT (n = 7) (14.2%) | 1 (14.2%) | |
ABCB1 C3435T | CC (n = 15) (30.6%) | 4 (26.6%) |
CT (n = 24) (48.9%) | 2 (8.3%) | |
TT (n = 10) (20.4%) | 2 (20.0%) |